AYA.AX Artrya Limited ASX after-hours 09 Mar 2026: A$3.04 signals AI upside

AYA.AX stock closed after-hours at A$3.04, down A$0.06 on the session but within a tight intraday range of A$2.94–A$3.19. Investors are watching Artrya Limited (ASX: AYA) for traction in its AI-powered Salix diagnostic platform and how clinical adoption will convert research spending into recurring revenue. The healthcare AI angle is the key driver for price action and near-term sentiment in Australia, where volume of 555,959.00 shares traded today shows steady retail and institutional interest.

AYA.AX stock: Price, volume and quick facts

Artrya Limited (AYA.AX) trades on the ASX in AUD and has a market capitalisation of A$386,920,000.00 with 113,800,000.00 shares outstanding. Today’s metrics: open A$3.16, previous close A$3.10, day low A$2.94, day high A$3.19, and volume 555,959.00 (average 618,748.00). The 50-day average is A$3.82 and the 200-day average is A$2.59, with a 52-week range of A$0.56–A$5.24.

Financials and valuation: AYA.AX stock fundamentals

Artrya reports trailing EPS of -0.19 and a negative PE of -17.89, reflecting development-stage losses and R&D investment. Cash per share stands at A$0.61, book value per share A$0.71, and current ratio is exceptionally high at 37.11, driven by working capital holdings of A$83,884,000.00. Price-to-book is 4.79, and price-to-sales is elevated at 13,342.07, implying the market values future software adoption more than current revenue.

Technical and trading signals for AYA.AX stock

Momentum is neutral: RSI 50.77, MACD -0.15 with a histogram of 0.04, and ADX 20.52 indicating no strong trend. Volatility measures show ATR 0.26 and Bollinger bands at 2.92–3.55, so current price sits near the middle band. On balance volume is negative and relative volume is 1.25, showing slightly higher activity versus average. Traders should watch 50-day resistance at A$3.82 and 200-day support at A$2.59.

Growth, risks and sector context for AYA.AX stock

Artrya operates in Healthcare — Medical Information Services — where peers show mixed margins and elevated valuations. Artrya spent 84.34% of revenue on R&D TTM, signalling deep product investment. Major risks: negative margins (net profit margin -679.59%), low revenue per share A$0.00, and long sales cycles for hospital adoption. Opportunities: Salix AI scaling, contract wins, and international trials that could drive recurring SaaS-like revenue.

Meyka grade and analyst-style verdict for AYA.AX stock

Meyka AI rates AYA.AX with a score out of 100: 63.40 / 100 — Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company receives positive marks for low leverage (debt-to-equity 0.01) and strong cash buffers, offset by negative profitability and high price-to-sales. These grades are not guarantees and are for informational use only.

Recent news, catalysts and how AI drives the outlook

Artrya’s Salix platform remains the primary catalyst: regulatory progress, pilot wins, or hospital rollouts would be immediate price drivers. No formal price target consensus is available, but the market is watching the next earnings announcement on 2026-08-27. For background reporting and company profile see stockanalysis and a peer comparison reference at Investing.com. For our real-time data and stock page see the Meyka AYA.AX page.

Final Thoughts

Key takeaways: AYA.AX stock trades at A$3.04, with mixed technicals and development-stage fundamentals. Short-term trading will be sensitive to adoption news, trial results and contract wins for Salix. Meyka AI’s forecast model projects a monthly level of A$3.05, a quarterly target of A$4.36 (implied upside 43.42% vs current price), and a 1-year projection of A$7.41 (implied upside 143.70%). These model-based projections compare to current fundamentals: EPS -0.19, PE -17.89, and market cap A$386,920,000.00. Investors should weigh high R&D intensity and long sales cycles against the potential for scalable AI diagnostics revenue. Forecasts are model-based projections and not guarantees. Meyka AI provides this analysis as an AI-powered market analysis platform to inform research, not as personalised advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.